FDA's Emergency Use Authorization for Malaria Drugs Could Hinder Trials of Other COVID-19 Treatments

Questions linger about the role the White House played in pushing the EUA, which comes with large product donations from Bayer and Sandoz that are expected to alleviate supply chain pressures for the drugs. 

Corona patient

The US Food and Drug Administration’s approval this weekend of an emergency use authorization (EUA) for two antimalarial drugs for COVID-19 may complicate clinical trials being conducted during the pandemic, experts say.

More from Clinical Trials

More from R&D